The increasing awareness about AATD, the relatively ease to target hepatocytes and the simple genetic basis led to a surge in clinical trials targeting intrahepatic synthesis and processing of the mutated AAT [21]. Here, SERPINA1 is linked to alpha 1-antitrypsin deficiency.